HGC Investment Management Inc. acquired a new stake in R1 RCM Inc. (NASDAQ:RCM – Free Report) in the third quarter, Holdings Channel.com reports. The fund acquired 30,494 shares of the healthcare provider’s stock, valued at approximately $432,000.
Other hedge funds have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD raised its stake in shares of R1 RCM by 5.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 89,342 shares of the healthcare provider’s stock valued at $1,151,000 after acquiring an additional 4,670 shares in the last quarter. QRG Capital Management Inc. grew its holdings in R1 RCM by 10.6% during the 2nd quarter. QRG Capital Management Inc. now owns 11,307 shares of the healthcare provider’s stock worth $142,000 after acquiring an additional 1,080 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of R1 RCM in the 2nd quarter valued at approximately $213,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of R1 RCM by 26.3% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 43,902 shares of the healthcare provider’s stock valued at $551,000 after purchasing an additional 9,149 shares in the last quarter. Finally, Intact Investment Management Inc. purchased a new stake in shares of R1 RCM during the 2nd quarter worth $621,000. Institutional investors and hedge funds own 61.10% of the company’s stock.
R1 RCM Price Performance
RCM stock opened at $14.31 on Tuesday. The company has a market cap of $6.04 billion, a price-to-earnings ratio of -95.39 and a beta of 0.84. The company has a current ratio of 1.79, a quick ratio of 1.79 and a debt-to-equity ratio of 0.76. The firm has a 50 day moving average of $14.25 and a 200-day moving average of $13.54. R1 RCM Inc. has a 12-month low of $8.87 and a 12-month high of $15.12.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on RCM shares. Cantor Fitzgerald reiterated a “neutral” rating and issued a $14.30 price objective on shares of R1 RCM in a report on Friday, October 4th. Morgan Stanley lowered shares of R1 RCM from an “overweight” rating to an “equal weight” rating in a research note on Thursday, August 8th. TD Cowen restated a “hold” rating and issued a $14.30 price objective (down previously from $20.00) on shares of R1 RCM in a research note on Monday, August 5th. Finally, Truist Financial cut their target price on R1 RCM from $16.00 to $14.30 and set a “hold” rating on the stock in a research report on Thursday, August 8th. Thirteen research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $15.41.
View Our Latest Research Report on RCM
About R1 RCM
R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.
Further Reading
- Five stocks we like better than R1 RCM
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Zoom Video Communications Positioned for Growth in 2025
- Stock Market Upgrades: What Are They?
- 5 Dividend Aristocrats to Buy Now and Hold Through 2025
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- The 3 Best Consumer Staples Stocks for a Defensive Strategy
Want to see what other hedge funds are holding RCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for R1 RCM Inc. (NASDAQ:RCM – Free Report).
Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.